Category Archives: Healthcare Technology

Systemic Bio Opens State-of-the-Art Laboratory

for Hydrogel Scaffold Mfg, Organ-On-A-Chip R&D

HOUSTON, TX, Apr 6, 2023 – Systemic Bio, a 3D Systems company, announced the opening of its new headquarters for hydrogel scaffold manufacturing and organ-on-a-chip R&D to facilitate its mission to accelerate drug discovery and development. This state-of-the-art facility contains a cleanroom for bioprinted hydrogel production and is located in the TMC Innovation Factory Labs on the Texas Medical Center Campus in Houston. From this location, Systemic Bio’s engineers and scientists will continue the development and production of the company’s proprietary h-VIOS (human vascularized integrated organ systems) organ-on-a-chip platform.

(L-R) 3D Systems President & CEO, Dr. Jeffrey Graves, Systemic Bio CEO, Taci Pereira, & 3D Systems EVP, Healthcare Solutions, Menno Ellis along with the Systemic Bio team at the ribbon cutting of their new headquarters.

h-VIOS is a versatile organ-on-a-chip platform that can recapitulate several organ and disease functions. Composed of vascularized hydrogel scaffolds, the h-VIOS platform enables the survival and function of human cells, both healthy and diseased, as well as the delivery of drugs to these cells in a more physiological manner. The establishment and further validation of these systems has the potential to significantly reduce both the high costs and extended times required for pharmaceutical companies to bring new drugs to market. The new center of excellence for scaffold manufacturing will enable sterile and quality-controlled production of h-VIOS chips and plates to be used by Systemic Bio’s pharmaceutical partners in drug testing. To oversee manufacturing operations, Systemic Bio hired Jeremy Carter as its vice president of operations. Jeremy has more than ten years of experience with GMP and FDA-regulated biopharmaceutical production at leading biotech companies such as Grail and Thermo Fisher Scientific.

“The opening of this facility is a fantastic milestone in Systemic Bio’s journey to accelerate drug discovery and development and a leap forward for the field of bioprinting,” said Taci Pereira, CEO, Systemic Bio. “With cutting-edge Print-to-Perfusion bioprinting technology from 3D Systems, our new cleanroom, and an exceptional team of scientists and engineers, we can now manufacture patterned sterile hydrogel scaffolds for commercial use with unprecedented precision, quality, and scalability. This marks a pivotal shift for bioprinting – going from experimental research to full-scale production. The h-VIOS platform is just the beginning of what we can unlock in the biotech industry with this new capability, and we look forward to continuing to partner with pharmaceutical and biotech companies to pursue these new opportunities.”

Systemic Bio is working to establish multi-year partnerships with pharmaceutical companies that could lead to the discovery of promising new drugs using the h-VIOS platform. Beyond providing organ-on-a-chip test samples and services, Systemic Bio is also now partnering with biotechnology companies interested in leveraging its hydrogel manufacturing capability to produce scaffolds for their applications of interest. The company is also currently recruiting for several open positions. For more information, please visit the company’s website.

About Systemic Bio

Systemic Bio is a biotech company focused on the application of advanced bioprinting technologies to pharmaceutical drug discovery and development. Founded in 2022 as a wholly-owned company of 3D Systems, Systemic Bio leverages 3D Systems’ breakthrough, production-level bioprinting technology to create extremely precise vascularized organ and disease models using biomaterials and human cells. These proprietary organs-on-chips can be manufactured reproducibly in large quantities and then perfused with drugs to study the effects on healthy or diseased tissue at the earliest stages of pharmaceutical drug development.

More information on the company is available at

Medtronic, NVIDIA to Build AI Platform for Medical Devices

NVIDIA announced that it is collaborating with Medtronic, the world’s largest healthcare technology provider, to accelerate the development of AI in the healthcare system and bring new AI-based solutions into patient care.

The companies will integrate NVIDIA healthcare and edge AI technologies into Medtronic’s GI Genius intelligent endoscopy module, developed and manufactured by Cosmo Pharmaceuticals. GI Genius is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.

GI Genius has been designed to host a suite of AI algorithms and integrating the NVIDIA Clara healthcare platform could allow Medtronic to scale development of algorithms for real-time procedures, potentially accelerating AI innovation for better patient care.

“Artificial intelligence is a powerful tool that can increase the speed, efficiency and effectiveness of global health systems,” said Kimberly Powell, vice president of healthcare at NVIDIA. “We’re collaborating with Medtronic to accelerate AI innovation by enabling a software-defined business model, with the goal of improving clinical decision making, reducing medical variability and driving better patient outcomes.”

“We believe that collaborating with AI companies and developers like NVIDIA and Cosmo is essential to driving innovation within the medical device industry,” said Giovanni Di Napoli, president of Gastrointestinal Business at Medtronic. “We are committed to working with the best and brightest minds in the field of AI to develop new technologies that can improve patient outcomes and transform the way we approach healthcare.”

Medtronic intends to integrate NVIDIA Holoscan — a real-time AI computing software platform for building medical devices — and NVIDIA IGX, an industrial-grade edge AI hardware platform, to run with its GI Genius AI-assisted colonoscopy system to support physicians with AI-enhanced diagnostic images. Holoscan helps bring the latest AI applications into clinical settings by providing the full-stack infrastructure needed for scalable, software-defined processing of streaming data at the edge.

The NVIDIA Holoscan and IGX platform makes software-defined medical devices possible by enabling developers to efficiently train and validate AI models within the Cosmo Innovation Center, and then host the AI-powered applications on Medtronic’s GI Genius AI Access Platform, a marketplace for software-as-a-medical-device (SaMD) applications.

The first GI Genius systems built with the NVIDIA technology will be available later this year.

Watch NVIDIA founder and CEO Jensen Huang discuss the Medtronic collaboration in his GTC keynote.


Since its founding in 1993, NVIDIA has been a pioneer in accelerated computing. The company’s invention of the GPU in 1999 sparked the growth of the PC gaming market, redefined computer graphics, ignited the era of modern AI and is fueling the creation of the metaverse. NVIDIA is now a full-stack computing company with data-center-scale offerings that are reshaping industry.

For more information, visit

Allucent Expands Use of Medidata Clinical Cloud

NEW YORK, NY, Mar 8, 2023 – Medidata, a Dassault Systèmes company, announced that Allucent, a contract research organization (CRO) bringing innovation to biopharma companies, is expanding the global use of Medidata’s Clinical Cloud to advance its end-to-end clinical trial operations offering.

The agreement expands Allucent’s existing utilization of Medidata technologies. These include Rave EDCeCOARTSM, and Rave Imaging, in support of critical areas of development, including oncology, rare and orphan indications, and cell and gene therapies. As part of this agreement, Allucent’s team also achieved 100% Rave EDC certification, reinforcing their commitment to quality, and providing their clients with best-in-class technology.

“Our partnership with Medidata allows us to continue to bring our customers the level of patient focus and insights they need and expect,” said Emily Moore, president of Biometrics at Allucent. “Making the Medidata Clinical Cloud platform available to our clients was an important step to enabling us to accelerate clinical trial development for our customers – small and mid-sized biotech companies.”

“Allucent is leveraging the power of the Medidata Clinical Cloud to solidify their position at the forefront of clinical technology,” said Janet Butler, head of Global Sales at Medidata. “Their work with novel therapies requires agile, patient-centric solutions. We are proud to build on our eight-year collaboration to advance the digital transformation of life sciences and deliver clinical innovations to help reach their goals.”

Allucent, a sponsor of Medidata NEXT London, will make a presentation on data analytics for early phase oncology trials. This includes how working with Medidata has helped them apply strategies and visualization techniques to extract the full value of information for all stakeholders.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,700+ customers and partners access the world’s most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company, is headquartered in New York City and has offices around the world to meet the needs of its customers.

For more information, visit

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE company, is a catalyst for human progress. They provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers.  Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries.

For more information, visit